vs
Side-by-side financial comparison of Amarin Corp plc (AMRN) and Exzeo Group, Inc. (XZO). Click either name above to swap in a different company.
Exzeo Group, Inc. is the larger business by last-quarter revenue ($55.5M vs $45.1M, roughly 1.2× Amarin Corp plc). Exzeo Group, Inc. runs the higher net margin — 36.7% vs -23.3%, a 60.0% gap on every dollar of revenue. On growth, Amarin Corp plc posted the faster year-over-year revenue change (7.0% vs 6.0%).
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.
Exzeo Group, Inc. is a global technology firm specializing in cloud-native SaaS solutions for the insurance industry. Its core product portfolio includes claims processing platforms, policy administration tools, and underwriting automation systems, serving insurance carriers, third-party administrators, and independent adjusters across North America and European markets.
AMRN vs XZO — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $45.1M | $55.5M |
| Net Profit | $-10.5M | $20.4M |
| Gross Margin | — | 59.0% |
| Operating Margin | 35.5% | 45.2% |
| Net Margin | -23.3% | 36.7% |
| Revenue YoY | 7.0% | 6.0% |
| Net Profit YoY | 33.0% | 13.7% |
| EPS (diluted) | — | $0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $45.1M | $55.5M | ||
| Q4 25 | $49.2M | $53.3M | ||
| Q3 25 | $49.7M | $55.2M | ||
| Q2 25 | $72.7M | — | ||
| Q1 25 | $42.0M | — | ||
| Q4 24 | $62.3M | — | ||
| Q3 24 | $42.3M | — | ||
| Q2 24 | $67.5M | — |
| Q1 26 | $-10.5M | $20.4M | ||
| Q4 25 | $-1.2M | $22.0M | ||
| Q3 25 | $-7.7M | $21.2M | ||
| Q2 25 | $-14.1M | — | ||
| Q1 25 | $-15.7M | — | ||
| Q4 24 | $-48.6M | — | ||
| Q3 24 | $-25.1M | — | ||
| Q2 24 | $1.5M | — |
| Q1 26 | — | 59.0% | ||
| Q4 25 | 47.1% | 65.4% | ||
| Q3 25 | 44.7% | 61.2% | ||
| Q2 25 | 69.2% | — | ||
| Q1 25 | 59.8% | — | ||
| Q4 24 | -15.4% | — | ||
| Q3 24 | 38.5% | — | ||
| Q2 24 | 63.4% | — |
| Q1 26 | 35.5% | 45.2% | ||
| Q4 25 | -12.9% | 50.3% | ||
| Q3 25 | -22.4% | 49.4% | ||
| Q2 25 | -22.0% | — | ||
| Q1 25 | -39.9% | — | ||
| Q4 24 | -84.3% | — | ||
| Q3 24 | -59.5% | — | ||
| Q2 24 | -0.8% | — |
| Q1 26 | -23.3% | 36.7% | ||
| Q4 25 | -2.5% | 41.2% | ||
| Q3 25 | -15.6% | 38.3% | ||
| Q2 25 | -19.4% | — | ||
| Q1 25 | -37.4% | — | ||
| Q4 24 | -78.0% | — | ||
| Q3 24 | -59.4% | — | ||
| Q2 24 | 2.3% | — |
| Q1 26 | — | $0.22 | ||
| Q4 25 | $0.00 | $0.25 | ||
| Q3 25 | $-0.02 | $0.25 | ||
| Q2 25 | $-0.03 | — | ||
| Q1 25 | $-0.04 | — | ||
| Q4 24 | $-0.12 | — | ||
| Q3 24 | $-0.06 | — | ||
| Q2 24 | $0.00 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $307.8M | $231.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $274.9M |
| Total Assets | $645.8M | $379.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $307.8M | $231.4M | ||
| Q4 25 | $302.6M | $305.4M | ||
| Q3 25 | $286.6M | $140.9M | ||
| Q2 25 | $298.7M | — | ||
| Q1 25 | $281.8M | — | ||
| Q4 24 | $294.2M | — | ||
| Q3 24 | $305.7M | — | ||
| Q2 24 | $306.7M | — |
| Q1 26 | — | $274.9M | ||
| Q4 25 | $459.3M | $254.2M | ||
| Q3 25 | $458.9M | $78.4M | ||
| Q2 25 | $464.9M | — | ||
| Q1 25 | $473.7M | — | ||
| Q4 24 | $486.2M | — | ||
| Q3 24 | $531.4M | — | ||
| Q2 24 | $551.9M | — |
| Q1 26 | $645.8M | $379.8M | ||
| Q4 25 | $670.8M | $347.7M | ||
| Q3 25 | $659.8M | $182.3M | ||
| Q2 25 | $670.1M | — | ||
| Q1 25 | $655.7M | — | ||
| Q4 24 | $685.3M | — | ||
| Q3 24 | $750.6M | — | ||
| Q2 24 | $799.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | — |
| Free Cash FlowOCF − Capex | — | $25.1M |
| FCF MarginFCF / Revenue | — | 45.3% |
| Capex IntensityCapex / Revenue | — | 0.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $15.3M | — | ||
| Q3 25 | $-12.7M | $89.0M | ||
| Q2 25 | $16.6M | — | ||
| Q1 25 | $-12.5M | — | ||
| Q4 24 | $-13.3M | — | ||
| Q3 24 | $-2.4M | — | ||
| Q2 24 | $-2.7M | — |
| Q1 26 | — | $25.1M | ||
| Q4 25 | — | $97.5M | ||
| Q3 25 | — | $86.6M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | 45.3% | ||
| Q4 25 | — | 182.8% | ||
| Q3 25 | — | 156.9% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | 0.6% | ||
| Q4 25 | — | 5.3% | ||
| Q3 25 | — | 4.4% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 4.21× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -1.81× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMRN
| U.S | $35.6M | 79% |
| Europe | $4.9M | 11% |
| Rest-of-World (ROW) | $2.8M | 6% |
| Licensing & Royalties | $1.8M | 4% |
XZO
Segment breakdown not available.
